his rbd beta  (Sino Biological)

Journal: Signal Transduction and Targeted Therapy

Article Title: Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2

doi: 10.1038/s41392-025-02551-x

Figure Lengend Snippet: SARS-CoV-2-induced CD147 up-regulation causes extended virus infection and pathological injury. a A flow chart for establishing hCD147 mice model of COVID-19. b The virus loads in the lung tissues of hCD147 mice were detected by Taqman-based RT-PCR at 3 and 7 dpi, *** p < 0.001. c , d ,The expression of CD147 was evaluated by western blot in the lung tissues of virus-infected hCD147 mice at 3 and 7 dpi, and the lung tissues of healthy hCD147 mice were used as the control ( c ). The relative expression level of CD147 was analyzed by Image Lab software, *** p < 0.001 ( d ). e The scRNA-seq identified the expression of CD147 in virus-infected ( n = 4,203) and virus-uninfected ( n = 13,354) cells of lung tissues from hCD147 mice. Wilcoxon test, p < 0.0001. f The scRNA-seq identified the expression of CD147 in virus-infected and virus-uninfected AT2 cells of lung tissues from hCD147 mice. g –i Infected, border, and uninfected regions in the lung tissues of virus-infected hCD147 mice were defined using spatial transcriptomics ( g ). The total expression of CD147 was quantified in three defined regions ( h ), and the expression of CD147 in AT2, M2 macrophages, and fibroblasts was determined ( i ). The number of spots used for data analysis in uninfected, border, and infected group were 312, 3,554, and 1,833, respectively. Wilcoxon test, p < 0.05, p < 0.001. j The BEAS-2B cells with SARS-CoV-2 pseudovirus infection in the upper chamber were co-cultured with the BEAS-2B cells in the lower chamber for 48 h, and the expression of CD147 in cells collected from the lower chamber were detected by western blot. k , l The expression of CD147 was determined by western blot in BEAS-2B cells with SARS-CoV-2 pseudovirus infection ( k ) or RBD incubation ( l ). m The relative luciferase signals in pseudovirus-infected BEAS-2B cells were determined by dual-luciferase reporter assays with RBD incubation, *** p < 0.001. n The relative luciferase signals in pseudovirus-infected BEAS-2B cells were determined by dual-luciferase reporter assays, ns, not significant, *** p < 0.001. o The virus loads in authentic virus-infected BEAS-2B cells were determined by Taqman-based RT-PCR, ns, not significant, ** p < 0.01, *** p < 0.001. p A flow chart for establishing a virus-infected hCD147 mouse model by primarily inoculating with RBD protein followed by authentic virus infection. q The expression of CD147 was detected in the lung tissues of hCD147 mice with His-RBD ( n = 4) or His-tag ( n = 4) inoculation and hCD147 mice with His-RBD ( n = 4) or His-tag ( n = 4) inoculation followed by authentic virus infection. r The virus loads in the lung tissues of virus-infected hCD147 mice were determined, * p < 0.05. s , t The infiltration of F4/80+iNOS+ M1 macrophages and Ly6G+ neutrophils in lung tissues of virus-infected hCD147 mice was evaluated by multicolor immunofluorescence staining, Ly6G, yellow; F4/80, green; iNOS, red, scale bar, 100 μm ( s ), and their infiltrated percentages were quantified, ** p < 0.01, *** p < 0.001 ( t ). u The level of cytokines and chemokines in lung tissues of virus-infected hCD147 mice was performed by RT-PCR, * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: The mobile phases contained the mutants of CD147 (His-CD147-R54A, His-CD147-E84A, His-CD147-E92A, His-CD147-Q100A, His-CD147-S112A, our laboratory), the mutants of RBD (His-RBD-G413A, His-RBD-K417A, His-RBD-K424A, His-RBD-G447A, His-RBD-Y489A, Sino Biological), His-RBD (WT) (40592-V08H, Sino Biological), His-RBD (Beta) (40592-V08H85, Sino Biological), His-RBD (Gamma) (40592-V08H86, Sino Biological), His-RBD (JN.1) (40592-V08H155, Sino Biological), rhesus macaque CD147 (Sino Biological), human ACE2 (Sino Biological), and rhesus macaque ACE2 (Sino Biological).

Techniques: Virus, Infection, Reverse Transcription Polymerase Chain Reaction, Expressing, Western Blot, Control, Software, Cell Culture, Incubation, Luciferase, Multicolor Immunofluorescence Staining

Journal: Vaccines

Article Title: First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

doi: 10.3390/vaccines12111288

Figure Lengend Snippet: Incidence of solicited local ( A ) and systemic ( B ) adverse events within the first 7 days following Prime-2-CoV_Beta vaccination. Day 1 represents the day of vaccination. AEs were categorized as mild (grade 1), moderate (grade 2), severe (grade 3), and life-threatening (grade 4). All AEs reported during this 7-day period are recorded.

Article Snippet: Briefly, 96-well microplates (Thermo Fisher, 442404, Hampton, NH, USA) were coated overnight at 4 °C with 1 µg/mL of recombinant S1 (eEnzyme, SCV2-S1-150P, Gaithersburg, MD, USA), RBD (Sino Biological, 40592-V08H, Beijing, China), nucleocapsid (Sino Biological, 40588-V08B), and RBD-Beta (Sino Biological, 40592-V08H85).

Techniques:

Journal: Vaccines

Article Title: First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

doi: 10.3390/vaccines12111288

Figure Lengend Snippet: Overall summary of adverse events following Prime-2-CoV_Beta vaccination. Data are n (%). Solicited AEs from cohort 1 (3 × 10 4 PFU/dose), cohort 2 (3 × 10 5 PFU/dose), cohort 3 (3 × 10 6 PFU/dose), cohort 4 (1.5 × 10 7 PFU/dose), and cohort 5 (3 × 10 7 PFU/dose) were reported within the first 7 days after vaccination. Each type of AE is counted only once per participant, and only the most severe occurrence is recorded.

Article Snippet: Briefly, 96-well microplates (Thermo Fisher, 442404, Hampton, NH, USA) were coated overnight at 4 °C with 1 µg/mL of recombinant S1 (eEnzyme, SCV2-S1-150P, Gaithersburg, MD, USA), RBD (Sino Biological, 40592-V08H, Beijing, China), nucleocapsid (Sino Biological, 40588-V08B), and RBD-Beta (Sino Biological, 40592-V08H85).

Techniques: Injection

Journal: Vaccines

Article Title: First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

doi: 10.3390/vaccines12111288

Figure Lengend Snippet: Summary of solicited local and systemic adverse events following Prime-2-CoV_Beta vaccination. The number of participants who had reported solicited local and systemic AEs within 7 days post-immunization. AEs were categorized as mild (grade 1), moderate (grade 2), severe (grade 3), and life-threatening (grade 4). Each type of AE is counted only once per participant, and only the most severe occurrence is recorded. C1-C5 denotes the Cohorts 1–5, respectively.

Article Snippet: Briefly, 96-well microplates (Thermo Fisher, 442404, Hampton, NH, USA) were coated overnight at 4 °C with 1 µg/mL of recombinant S1 (eEnzyme, SCV2-S1-150P, Gaithersburg, MD, USA), RBD (Sino Biological, 40592-V08H, Beijing, China), nucleocapsid (Sino Biological, 40588-V08B), and RBD-Beta (Sino Biological, 40592-V08H85).

Techniques:

Journal: Vaccines

Article Title: First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

doi: 10.3390/vaccines12111288

Figure Lengend Snippet: SARS-CoV-2 spike- and nucleocapsid-specific antibody responses following Prime-2-CoV_Beta vaccination. IgG binding antibody levels against the S1 subunit of spike of the ancient SARS-CoV-2 ( A ), the RBD of spike of the ancient SARS-CoV-2 ( B ), the RBD of spike of the SARS-CoV-2 Beta variant ( C ), and of the nucleocapsid of the ancient SARS-CoV-2 ( D ) as measured in serum samples obtained from vaccinated participants at indicated time points by a validated in-house ELISA. Logarithmic values are reported as the geometric mean titer (GMT), and the bars represent the geometric mean with a 95% CI. Fold change from Day 29 to baseline is denoted above the columns. GMT at each time point is indicated in the columns. LLOQ = Lower Limit of Quantification is indicated by the dotted line. For pairwise comparisons of time points within each dose group, the Friedman test was used, followed by the Wilcoxon signed-rank test if the Friedman test was significant ( p -value ≤ 0.05). * p < 0.05; ** p < 0.01.

Article Snippet: Briefly, 96-well microplates (Thermo Fisher, 442404, Hampton, NH, USA) were coated overnight at 4 °C with 1 µg/mL of recombinant S1 (eEnzyme, SCV2-S1-150P, Gaithersburg, MD, USA), RBD (Sino Biological, 40592-V08H, Beijing, China), nucleocapsid (Sino Biological, 40588-V08B), and RBD-Beta (Sino Biological, 40592-V08H85).

Techniques: Binding Assay, Variant Assay, Enzyme-linked Immunosorbent Assay

Journal: Vaccines

Article Title: First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

doi: 10.3390/vaccines12111288

Figure Lengend Snippet: SARS-CoV-2 neutralization response following Prime-2-CoV_Beta vaccination to ancestral SARS-CoV-2, Beta, Delta, and BA.5. Neutralizing antibody levels against the ancient SARS-CoV-2 ( A ), the SARS-CoV-2 Beta variant ( B ), the SARS-CoV-2 Delta variant ( C ), and the SARS-CoV-2 Omicron BA.5 variant ( D ) as measured in serum samples obtained from vaccinated participants at indicated time points by a validated microneutralization assay. Logarithmic values are reported as the GMT, and the bars represent the geometric mean with a 95% CI. Fold change from Day 29 to baseline is denoted above the columns. GMT at each time point is indicated in the columns. LLOQ = lower limit of quantification is indicated by the dotted line. For pairwise comparisons of time points within each dose group, the Friedman test was used, followed by the Wilcoxon signed-rank test if the Friedman test was significant ( p -value ≤ 0.05).

Article Snippet: Briefly, 96-well microplates (Thermo Fisher, 442404, Hampton, NH, USA) were coated overnight at 4 °C with 1 µg/mL of recombinant S1 (eEnzyme, SCV2-S1-150P, Gaithersburg, MD, USA), RBD (Sino Biological, 40592-V08H, Beijing, China), nucleocapsid (Sino Biological, 40588-V08B), and RBD-Beta (Sino Biological, 40592-V08H85).

Techniques: Neutralization, Variant Assay, Microneutralization Assay

Journal: Vaccines

Article Title: First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

doi: 10.3390/vaccines12111288

Figure Lengend Snippet: ORFV-specific immune response and ORFV neutralization following Prime-2-CoV_Beta vaccination. IgG binding antibody levels ( A ) and neutralizing antibody levels ( B ) against ORFV strain D1701-VrV as measured in serum samples obtained from vaccinated participants at indicated time points by ELISA or microneutralization assay, respectively. Logarithmic values are reported as the GMT, and the bars represent the geometric mean with a 95% CI. Fold change from Day 29 to baseline is denoted above the columns. GMT at each time point is indicated in the columns. LLOQ = lower limit of quantification is indicated by the dotted line. For pairwise comparisons of time points within each dose group, the Friedman test was used, followed by the Wilcoxon signed-rank test if the Friedman test was significant ( p -value ≤ 0.05). * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: Briefly, 96-well microplates (Thermo Fisher, 442404, Hampton, NH, USA) were coated overnight at 4 °C with 1 µg/mL of recombinant S1 (eEnzyme, SCV2-S1-150P, Gaithersburg, MD, USA), RBD (Sino Biological, 40592-V08H, Beijing, China), nucleocapsid (Sino Biological, 40588-V08B), and RBD-Beta (Sino Biological, 40592-V08H85).

Techniques: Neutralization, Binding Assay, Enzyme-linked Immunosorbent Assay, Microneutralization Assay